Device Trial Radar · NCT05641753
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
125
Planned (sponsor's estimate)
Start
Dec 6, 2022
Primary completion
Jul 1, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, interventional, cohort study, meaning that researchers will follow and observe a group of enrolled study participants over a period of time (one to two months) to gather information and record any developments of the outcomes in question. This study will recruit 125 participants with Type 1 Diabetes (T1D) to: 1. Analyze the effect of reducing the cholesterol levels in the blood on platelet function. (Platelets are small cells in the blood which help form blood clots to slow or stop bleeding and to help wounds heal 2. Analyze the effect of reducing the cholesterol levels in the blood on While Blood Cell (WBC) gene expression, (White Blood Cells are part of the body's immune system which help the body fight infection and other diseases) and 3. Analyze the effect of reducing the cholesterol levels in the blood on vascular or blood vessel function.
Conditions
- Type 1 Diabetes
Interventions
Evolocumab CartridgeDrug
Injectable PCSK9 inhibitor.
Atorvastatin Calcium TabletsDrug
HMG-CoA reductase inhibitor for oral use.
Ezetimibe TabletsDrug
Will only be distributed to patients with statin intolerance; replacement for both Atorvastatin and Evolocumab. Inhibitor of intestinal cholesterol for oral use.
18F-FDGDrug
Optional procedure. Positron emission tomography (PET) and computed tomography (CT) imaging to assess vascular inflammation and related anatomy requires injection of the PET tracer 18F-FDG. 18F-FDG is an FDA-approved analogue of sugar, routinely used to evaluate elevated metabolism in tissues, including increased metabolism due to inflammatory cells. A standard dose of 7.0 mSv will be administered.
Angiocatheter 20IVDevice
Optional procedure (endothelial cell harvesting). An angiocatheter ≤ 21 gauge will be inserted into a peripheral vein on the upper extremity using aseptic technique. A 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be then advanced into the angiocatheter, to a distance of 4cm beyond the end of the angiocatheter.
J-WireDevice
Optional procedure (endothelial cell harvesting). Either a 0.021in. diameter J-shaped wire (Daig, Minnetonka, MN) or a 0.018in. diameter J-shaped wire (Arrow, Reading, PA) will be used.
GlycoCheck Glycocalyx Measurement SoftwareDevice
Optional procedure (assessment of vascular function). Video microscope developed by GlycoCheck.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Monocyte Platelet Aggregation (MPA) from BaselineTime frame: Baseline, Week 4
- Change in Light Transmission Aggregation (LTA) from BaselineTime frame: Baseline, Week 4
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
New York VA Hospital
New York, New York · Recruiting
NYC Health + Hospitals/Bellevue
New York, New York · Recruiting
NYU Langone Health
New York, New York · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.